S&P 500
(0.02%) 5 071.63 points
Dow Jones
(-0.11%) 38 461 points
Nasdaq
(0.10%) 15 713 points
Oil
(-0.70%) $82.78
Gas
(-9.22%) $1.645
Gold
(-0.54%) $2 329.50
Silver
(-0.62%) $27.19
Platinum
(-1.11%) $912.55
USD/EUR
(0.06%) $0.935
USD/NOK
(0.76%) $10.99
USD/GBP
(-0.09%) $0.802
USD/RUB
(-1.00%) $92.26

Realtime updates for Eli Lilly and Co [LLY.DE]

Exchange: XETRA Sector: Pharmaceuticals Industry: Drug Manufacturers—General
Upcoming Earnings Alert

5 days till quarter result
(bmo 2024-04-29)

Expected move: +/- 0.00%

Last Updated24 Apr 2024 @ 11:35

-1.07% 686.20

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 11:35):

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes...

Stats
Today's Volume 1 639.00
Average Volume 6 535.00
Market Cap 652.42B
EPS €0 ( 2024-02-06 )
Next earnings date ( €1.550 ) 2024-04-29
Last Dividend €1.130 ( 2023-08-14 )
Next Dividend €0 ( N/A )
P/E 126.84
ATR14 €1.233 (0.18%)

Volume Correlation

Long: 0.12 (neutral)
Short: 0.39 (neutral)
Signal:(43.019) Neutral

Eli Lilly and Co Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Eli Lilly and Co Correlation - Currency/Commodity

The country flag -0.15
( neutral )
The country flag -0.28
( neutral )
The country flag 0.22
( neutral )
The country flag -0.25
( neutral )
The country flag 0.63
( weak )
The country flag -0.49
( neutral )

Eli Lilly and Co Financials

Annual 2023
Revenue: €34.12B
Gross Profit: €27.04B (79.25 %)
EPS: €5.82
Q4 2023
Revenue: €9.35B
Gross Profit: €7.57B (80.88 %)
EPS: €2.31
Q3 2023
Revenue: €9.50B
Gross Profit: €7.64B (80.42 %)
EPS: €-0.0638
Q2 2023
Revenue: €8.31B
Gross Profit: €6.50B (78.26 %)
EPS: €1.960

Financial Reports:

No articles found.

Eli Lilly and Co Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
€0.980
(N/A)
€0.980
(N/A)
€1.130
(N/A)
€1.130
(N/A)
€1.130
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)

Eli Lilly and Co Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 5.72 - average (57.84%) | Divividend Growth Potential Score: 6.05 - Stable (21.06%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend €0.490 2009-05-13
Last Dividend €1.130 2023-08-14
Next Dividend €0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 41 --
Total Paid Out €27.35 --
Avg. Dividend % Per Year 0.00% --
Score 3.68 --
Div. Sustainability Score 5.72
Div.Growth Potential Score 6.05
Div. Directional Score 5.89 --
Next Divdend (Est)
(2024-09-05)
€1.166 Estimate 20.00 %
Dividend Stability
0.53 Average
Dividend Score
3.68
Pay Frequency
Quarterly
Yearly Payout
Year Amount Yield

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for XETRA

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
VODI.DE Ex Dividend Knight 2023-06-08 Semi-Annually 0 0.00%
FPMB.DE Ex Dividend King 2023-10-12 Quarterly 0 0.00%
OHB.DE Ex Dividend Junior 2023-05-26 Annually 0 0.00%
BAS.DE Ex Dividend Knight 2023-04-28 Annually 0 0.00%
HEN3.F Ex Dividend Knight 2023-04-25 Annually 0 0.00%
RHM.DE Ex Dividend Knight 2023-05-10 Annually 0 0.00%
CHV.DE Ex Dividend King 2023-08-17 Quarterly 0 0.00%
JST.DE Ex Dividend Junior 2023-05-12 Sporadic 0 0.00%
185.DE Ex Dividend Junior 2023-08-07 Quarterly 0 0.00%
SZG.DE Ex Dividend Junior 2023-05-26 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.1541.5006.9310.00[0 - 0.5]
returnOnAssetsTTM0.08191.2007.278.73[0 - 0.3]
returnOnEquityTTM0.4741.5005.858.77[0.1 - 1]
payoutRatioTTM0.777-1.0002.23-2.23[0 - 1]
currentRatioTTM0.9430.800-0.287-0.230[1 - 3]
quickRatioTTM0.5230.800-1.632-1.305[0.8 - 2.5]
cashRatioTTM0.1031.500-0.537-0.806[0.2 - 2]
debtRatioTTM0.394-1.5003.43-5.15[0 - 0.6]
interestCoverageTTM15.001.0005.565.56[3 - 30]
operatingCashFlowPerShareTTM4.472.008.5110.00[0 - 30]
freeCashFlowPerShareTTM-3.322.00-1.660-3.32[0 - 20]
debtEquityRatioTTM2.34-1.5000.633-0.949[0 - 2.5]
grossProfitMarginTTM0.7921.0000.1260.126[0.2 - 0.8]
operatingProfitMarginTTM0.2141.0007.737.73[0.1 - 0.6]
cashFlowToDebtRatioTTM0.1681.000-0.177-0.177[0.2 - 2]
assetTurnoverTTM0.5330.8009.787.82[0.5 - 2]
Total Score5.72

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM135.801.00010.000[1 - 100]
returnOnEquityTTM0.4742.507.338.77[0.1 - 1.5]
freeCashFlowPerShareTTM-3.322.00-1.107-3.32[0 - 30]
dividendYielPercentageTTM0.6261.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM4.472.008.5110.00[0 - 30]
payoutRatioTTM0.7771.5002.23-2.23[0 - 1]
pegRatioTTM7.821.50010.000[0.5 - 2]
operatingCashFlowSalesRatioTTM0.1241.0009.390[0.1 - 0.5]
Total Score6.05

Eli Lilly and Co

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators